SC
BCRX icon

Schubert & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Schubert & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31
Closed -$259 – 193
2023
Q1 		$259 Sell
31
-13
-30% -$125 ﹤0.01% 1522
2022
Q4 		$505 Sell
44
-9
-17% -$112 ﹤0.01% 1384
2022
Q3 		$1K Buy
53
+16
+43% +$206 ﹤0.01% 1010
2022
Q2 		$0 Buy
37
+22
+147% +$227 ﹤0.01% 1439
2022
Q1 		$0 Buy
15
+11
+275% +$176 ﹤0.01% 1080
2021
Q4 		$0 Buy
+4
New +$53 ﹤0.01% 1015

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Schubert & Co's BCRX Position: Q2 2023 in Review

Schubert & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 31 shares — an estimated $259 sold.

Schubert & Co first reported a position in BCRX in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

  • Schubert & Co reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 31 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $259.
  • Schubert & Co first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's BioCryst Pharmaceuticals position peaked at $1K in Q3 2022.
  • 236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.